This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Rapamycin reduces primary effusion lymphoma progression by targeting VEGF production and VEGF responses
Infectious Agents and Cancer 2009, 4(Suppl 2):O12 doi:10.1186/1750-9378-4-S2-O12
Accesses
- Last 30 days: 15 accesses
- Last 365 days: 174 accesses
- All time: 521 accesses